

The Children's Tumor Foundation is conducting a survey to find out the extent to which the drug bevacizumab (better known by its trade name Avastin) has been/is currently being prescribed to individuals with NF2, both inside and outside the context of organized clinical trials. This information will be extremely helpful in understanding current use patterns of Avastin in the NF2 population. Collectively this data could be helpful in planning future clinical trials.

This survey may be taken anonymously

, please provide as much information and use as much space as you wish. You need not complete all questions if you are not sure how to respond to some.

You need not provide your name or your doctor/clinic name if you do not wish to.

The data collected through this survey will be collated, tabulated and graphed (e.g. to show number of respondents, responses to certain questions, etc.)

without identifying information on survey respondents

This data will be emailed to all survey respondents that provide an email address. The collective data may be shared with researchers/physicians and more publicly

without any information that identifies survey respondents

. □

[To download this survey as a Word document please click here](#) . [To download the survey as a pdf please click here](#)

Please email or FAX your completed survey responses to me - Dr. Kim Hunter-Schaedle - at // khs@ctf.org // This e-mail address is being protected from spambots. You need JavaScript enabled to view it // or 212-747-0004.